Reported about 7 hours ago
BMO Capital analyst Evan Seigerman highlights that a recent U.S. district court ruling favored Acadia Pharmaceuticals in a patent infringement case against Aurobindo, confirming that Aurobindo violated key claims of Acadia’s patent. This ruling could extend the patent protection for Acadia’s drug, pimavanserin, from 2030 to 2038, thereby removing a significant uncertainty for investors and maintaining an Outperform rating with a $24 price target on Acadia shares.
Source: YAHOO